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Background: The Scottish Government set out its policy on addressing the poor oral health of Scottish children in
2005. This led to the establishment of Childsmile, a national programme designed to improve the oral health of
children in Scotland. One element of the programme promotes daily tooth brushing in all nurseries in Scotland
(Childsmile Core). A second targeted component (Childsmile Nursery) offers twice-yearly application of fluoride
varnish to children attending nurseries in deprived areas. Studies suggest that fluoride varnish application can
reduce caries in both adult and child populations. This trial aims to explore the effectiveness and cost-effectiveness
of additional preventive value fluoride varnish application compared to Childsmile Core.
Methods/Design: The Protecting Teeth@3 Study is an ongoing 2 year parallel group randomised treatment as
usual controlled trial. Three-year-old children attending the ante pre-school year are randomised (1:1) to the
intervention arm (fluoride varnish & treatment as usual) or the control arm (treatment as usual). Children in the
intervention arm will have Duraphat® fluoride varnish painted on the primary tooth surfaces and will continue to
receive treatment as usual: the core Childsmile Nursery intervention. Children in the treatment as usual arm will
receive the same series of contacts, without the application of varnish and will also continue with the Childsmile
Core intervention. Interventions are undertaken by Childsmile trained extended duty dental nurses at six-monthly
intervals. Participants receive a baseline dental inspection in nursery and an endpoint inspection in Primary 1 at the
age of 5 years old.
We will use primary and secondary outcome measures to compare the effectiveness of Duraphat® fluoride varnish
plus treatment as usual with treatment as usual only in preventing any further dental decay. We will also undertake
a full economic evaluation of the trial.
Trial registration: This study is registered at ClinicalTrials.gov. Number: NCT01674933 (24 August 2012).
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This study will be performed according to the Research
Governance Framework for Health and Community
Care [6] and The Medicines for Human Use (Clinical
Trials) Regulations [24]) SI 2004:1031 (as amended), and
World Medical Association Declaration of Helsinki: Eth-
ical principles for medical research involving human
subjects 1964 (as amended). Amendment number 4,
Protocol version V2.3, 31st July 2015. Duraphat has been
considered to be an Investigational Medicinal Product
for the purposes of this trial. The notification from the
MHRA is shown in Additional file 1; the study has been
given the EUDRACT number 2012-002287-26. All in-
vestigators and key trial personnel will complete biennial
Good Clinical Practice training.
In 2005 the Scottish Government set out its policy on
addressing the poor oral health of Scottish children. A
series of reports had highlighted persistently high rates
of dental caries with significant inequalities in oral
health [16], low rates of NHS dental registration for
young children (35 % of 0–2 year-olds in 2004) [17], and
extremely limited preventive activity [18].
The 2005 Scottish Government Report “An Action
Plan for Improving Oral Health and Modernising Dental
Services in Scotland” announced what was to become
the Childsmile oral health improvement programme
[19]. The aim was to shift the balance of care towards
more preventive and anticipatory care and target the
early years in an attempt to promote health improve-
ment from a young age. Programme development was
founded on the principles outlined in the Ottawa Char-
ter for Health Promotion [30].
Two Childsmile Demonstration Programmes were sub-
sequently established in 2006, one in the East and one in
the West of Scotland, with a targeted approach to improv-
ing the oral health of young children. Both were to run
initially for 3 years, in order to allow the Programmes to
evolve as a result of ongoing monitoring, evaluation, and
stakeholder feedback. The Programmes complemented a
national toothpaste/toothbrushing scheme set up a few
years previously, whereby free toothpaste/toothbrush
packs are distributed to every child in Scotland on at
least six occasions during their first 5 years and free
daily toothbrushing offered to every 3 and 4 years old
child attending nursery schools in Scotland. The
toothbrushing programme is also available to primary one
and two children in schools situated in disadvantaged
areas of National Health Service (NHS) Boards across the
country. This programme, which became Childsmile Core,
built on pre-existing local NHS Board-based toothbrush-
ing initiatives, and enabled standardisation across the
country with national procurement of the toothbrushing
supplies and the publication and implementation of na-
tional standards for toothbrushing programmes [12, 13].In nursery schools - the setting for the present study -
Childsmile Core promotes daily tooth brushing, backed
up with free dental packs containing fluoride toothpaste
(circa 1000 ppm F), toothbrushes and advice leaflets,
fruit and freely available water. Children in nurseries in
deprived areas are also offered twice-yearly application
of fluoride varnish from the time they start nursery under
the Childsmile Nursery programme. In the period Decem-
ber 2006 to July 2011 168,000 Duraphat applications were
completed under this programme, with no reported sig-
nificant adverse events.
However, it is important to ascertain the additional
preventive value fluoride varnish application in nursery
schools may bestow over and above that gained from the
Childsmile Core activities described above. There is
some evidence from quasi-experimental data at the
population level that the Childsmile Core intervention
on its own has indeed improved the oral health of chil-
dren in the Greater Glasgow area [2, 3]. The study will
establish whether fluoride varnish will deliver benefits
which are additional to those of the Childsmile Core
Programme.
A systematic Cochrane Review of fluoride varnish appli-
cation (Marinho et al. [9] concluded that this treatment
reduced worsening of caries (known as a 'prevention frac-
tion') in the primary dentition by 33 %, as measured by
the 'd3mfs' score for deciduous teeth (number of decayed
(at the dentine level), missing and filled surfaces). At the
'd3mft' level (decayed missing and filled teeth), the amount
of prevented disease was possibly larger with an estimate
of 53 %. Most of the studies included in the review were
from populations with regular use of fluoride treatments,
especially toothpaste.
On the one hand it is known that many deprived chil-
dren in Scotland have not been using fluoride toothpaste
in the past, but on the other hand the Childsmile
programme should be addressing this problem. Perhaps
a 33–53 % reduction in worsening of dmfs/dmft is a rea-
sonable estimate of how much fluoride varnishes could
achieve in a deprived population in the West of Scotland.
However, the Cochrane review was only based upon nine
trials, and only two of these looked at the deciduous teeth
of 3 and 4 year olds. The 'numbers needed to treat' varied
from 3.7 in low caries populations to 1.6 in higher caries
populations.
A number of relevant studies have been published
since the 2002 review. A randomised controlled trial by
Skold et al. [21] involved Swedish schoolchildren being
assigned different frequencies of varnish treatment,
across three different levels of dental risk including a
'high risk' group. This study demonstrated a prevention
fraction for varnish at six-monthly intervals of 69 % in
high risk areas, 66 % in medium risk areas, and only
20 % in low risk areas. Although of great interest the
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so does not answer the specific questions addressed in
the present study. A German study reported by Borutta
et al. [4]) appears to be closer to the proposed study.
The aim was to assess the caries inhibition effect of
fluoride varnishes among preschool children with high
caries risk though an examiner-blind, clinically con-
trolled 2-year study with 200 randomly selected 2- to
4-year-olds. As with the present study, four varnish
applications were offered. The study reports a caries
reduction level of 57 % for the fluoride varnish com-
pared with controls. However there is no reference to
the study taking place within an established preven-
tion programme as represented by Childsmile Nursery
in the present study.
A third RCT [7] investigated the preventive effect of
fluoride varnish in primary school children aged around
7 years old. Randomisation was at the school year level
with either Primary 2 or Primary 3 receiving fluoride
varnish treatment. The percentage of children with in-
creased caries was high in both intervention (53 %) and
'treatment as usual' group (50 %). Weaknesses in this
study include the 'clustered within the same school' de-
sign (which could have encouraged compensatory action
to improve dental health in control classes), blinding
limited to the evaluator, and difficulties recruiting chil-
dren with a high risk of caries.
A recent trial involving schoolchildren in the North
West of England [10] also failed to find any evidence of
effectiveness of fluoride varnish in a public health
programme. However, the North West England trial was
undertaken in older children (aged 7–8 years old), while
the present study focuses on 3 and 4 year olds. In
addition the small amount of varnish used in the North
West England trial (3 applications of 22,600 ppm fluor-
ide varnish per year for 3 years) applied to permanent
molars may have been insufficient to provide effective
dental caries prevention. Finally, the present study takes
place within the Childsmile programme of supervised
nursery toothbrushing for children from more deprived
areas who may be more at risk of developing caries.
Study rationale – hypothesis
In nursery schools - the main setting for the present
study – the Scottish Government’s Childsmile Core
programme promotes daily tooth brushing, backed up
with free dental packs containing fluoride toothpaste
(circa 1000 ppm F), toothbrushes and advice leaflets,
fruit and freely available water. Children in nurseries in
deprived areas are also offered twice-yearly application
of fluoride varnish from the time they start nursery. It is
important to ascertain the additional preventive value
this may bestow over and above that gained from the
Childsmile Core activities described above. The studywill establish whether fluoride varnish will deliver bene-
fits which are additional to those of the Childsmile Core
Programme.
The null hypothesis is therefore that the dental health
(measured by d3mft score) of children in the fluoride
varnish arm of the study is no better after 18 months of
varnish application than that of the children in the TAU
arm. The alternative to the null hypothesis is that there
will be a significantly lower increase in the d3mft scores
of children in the fluoride varnish arm than that found
in the d3mft of children in the TAU arm.
Study objectives
The objective of this study is to compare the effective-
ness of Duraphat fluoride varnish plus treatment as
usual (TAU) with TAU only in preventing any further
dental decay. The primary endpoint for each individual
child is whether or not there has been any occurrence of
new caries lesions over the 2 year period, as measured
by any increase in d3mft at 2 years of follow up com-
pared to the d3mft at baseline (d3mft is dental decay as
measured by the dmft scale in the dentine).
Methods/Design
This protocol was peer reviewed by the national evalu-
ation board of the Childsmile Programme, which was set
up by the funder (Scottish Government) to have over-
sight of all research and evaluation that is associated
with the programme. The design is described diagrama-
tically in Fig. 1.
Study population
Eight hundred five children will be recruited into each
of the two arms of the study. They will be identified in
approximately 50 nursery schools in the NHS Lothian,
Greater Glasgow and Clyde, Fife and Tayside Health
Board areas. Nursery schools selected for this study will
serve children likely to be at a higher than average risk
of caries (e.g., because the nursery school serves a popu-
lation from postcode areas with a SIMD score indicating
higher social deprivation). The sample is 3-year-olds at-
tending participating nursery schools. Eligibility regard-
ing absence of contraindications will be assessed by
enquiries to parents and schools prior to study entry.
Routine Childsmile information on fluoride varnish will
be used, as well as the study information from a specially
designed ‘participant information sheet’ (PIS).
Eligible participants will be randomised (1:1) to receive
Duraphat ® fluoride varnish plus TAU or TAU only. Ran-
domisation will follow the baseline dental examination
by a study dental practitioner, and will take place via a
telephone call to the Interactive Voice Response System
(IRVS) at the Robertson Centre for Biostatistics, University
of Glasgow. Blocks of four and two will be used within
Fig. 1 Flow diagram of the PT@3 Study
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each of the two treatments will be allocated equally. Be-
cause the blocking is done at each nursery separately we
will not necessarily complete the last block at each of the
schools (i.e., when the target number of subjects in eachtreatment group has been reached). Members of the Ex-
tended Duty Dental Nurse (EDDN) teams undertake the
randomisation of participants and are allocated a Personal
Identification Number (PIN) by the RCB and trained in
the use of the IVRS.
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– Provision of a signed informed consent form from a
parent or legal guardian.
– Children in the first year of nursery school (known
as the ‘ante pre-school year’).
– Every eligible child in participating nurseries will be
invited to join the study, irrespective of the SIMD
ranking of their own postcode.
– Children with or without pre-existing cavities, as the
cavity can be treated through the usual primary care
dental service (i.e., as part of ‘treatment as usual’).Exclusion criteria
– Children with contraindications for the Duraphat
varnish i.e., hypersensitivity to colophony and/or any
other constituents.
– A history of bronchial asthma requiring
hospitalisation.
– History of allergic episodes requiring hospital
admission.Identification of participants and consent
Once the head teacher has given permission, an infor-
mation sheet and consent form will be given or sent to
the parents or guardians of every ante pre-school child.
The participant information sheet makes clear the dur-
ation of the trial and that participation is voluntary and
that the parent or guardian can withdraw their child at
any point. Child home postcodes from the school regis-
tration rolls will be linked to the Scottish Index of Mul-
tiple Deprivation (SIMD) to ensure any potential
participation bias can be analysed, and to ensure out-
comes can be assessed by deprivation.
Children will not be approached for consent/assent
due to their young age. Informed consent will be ob-
tained directly from the parents/guardians by members
of the study team at their child’s nursery, at the consent-
ing visit which will take place at least 24 h after the dis-
tribution of the PIS. Trial staff will also ask consenting
parents and guardians to complete a contraindications
checklist (adapted from the Childsmile Consent Form
for Toothbrushing & Fluoride Varnish [version 7.1]).
The checklist will screen children for the contraindica-
tions for Duraphat® varnish (listed above). All checklists
with information on possible contraindications will be
assessed to decide if the child should be excluded from
the trial. On the day of the dental inspection any child
showing distress or verbal or non-verbal signs of ex-
treme reluctance will be excluded from the study if the
dentists feel that continuing with the inspection would
cause the child further distress.Withdrawal of subjects
Immediately prior to the 6, 12, and 18 Month interven-
tions, parents/guardians will be requested to update in-
formation on contraindications to Duraphat® varnish.
Parents/guardians will be sent a self-complete version of
the Contraindications checklist (adapted from the Child-
smile Consent Form for Toothbrushing & Fluoride Var-
nish [version 7.1]) and a covering letter. The checklist
will again screen children for the contraindications for
Duraphat® varnish listed above. The covering letter
makes it clear that the checklist must be returned if the
child has developed any contraindications in the period
following the previous intervention, so we can exclude
that child from the intervention. All returned checklists
will be assessed by the trial dentist who will decide if the
reported contraindication for Duraphat® varnish requires
that the child be withdrawn from the study.
Parents who withdraw their child will be asked, if ap-
propriate, to agree to their having the end-of-study
dental examination, in order to make best use of infor-
mation already collected on that child. Children who
leave a trial nursery school during the study, but remain
in the local area, and go on to attend a local primary
school will receive an endpoint dental inspection. The
parents/guardians of these children will be informed of
the inspection.
Any adverse reactions to the fluoride varnish (e.g., mu-
cositis, allergic reaction etc.), whether noted by Child-
smile staff or reported by parents or school, will be
entered into the Case Report Form by the study dental
nurse or dental health support worker. All recorded ad-
verse reactions will be reviewed by the site Principal In-
vestigator. Details of adverse reactions will be assessed
against the criteria for expedited pharmacovigilance
reporting to the MHRA and Research Ethics Committee.
If any immediate adverse reaction is suspected, the var-
nish can be easily removed by toothbrushing, rinsing
and spitting. Any child with a suspected immediate ad-
verse reaction will be permanently withdrawn from the
study.
Study schedule
Up to six visits are involved for children who are
retained throughout the study. The first will be to
complete the baseline dental inspection. This is followed
by randomisation and the first of four intervention/TAU
visits by the study Childsmile team to the nursery
school, spaced roughly six months apart. The final visit
is to undertake an endpoint dental inspection to re-
inspect the child in year 1 of their primary school. Nei-
ther children nor parents are required to make special
visits to a clinic or other study base. Where possible,
visits 1 and 2 will be combined: i.e., if logistics allow, the
first varnish/TAU intervention will be completed after
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randomisation.
Visit 1/visit 2: Examination/randomisation/0 month
intervention visit(s)
At this visit study staff will confirm eligibility before the
baseline dental examination is carried out by a study
dental practitioner (e.g., signed consent form is in place,
enquiry form regarding contraindications is complete
and the child has no obvious temporary infections or in-
juries which would lead to exclusion on the day). Com-
pletion of CRF containing dental examination data.
All children receive treatment as usual (TAU), namely
supervised toothbrushing in the nursery. Randomisation
will take place via a telephone call to the IRVS at the
Robertson Centre for Biostatistics. As soon as possible
following randomisation, the study Childsmile team will
perform a brief oral check, depending on randomisation
they either get a “sham” fluoride varnish application (ap-
plicator brushing teeth with no fluoride varnish on it) or
they get the active treatment involving application of
fluoride varnish. The dental nurse will record treatment
arm in order to ensure consistency of treatment
throughout the sequence of visits.
Visit 3: 6 Month (+/- 3 months) intervention visit to nursery
school
In the week prior to the visit parents will be sent the
contraindications checklist and covering letter (detailed
above). If the parents are aware of any contraindications
this checklist will be returned to the nursery school. On
arrival at the nursery school the study dental team will
ascertain if any checklists have been returned. If no ex-
clusion criteria are identified, the study dental team will
again either apply fluoride varnish, or deliver TAU, in-
cluding a brief oral check, as dictated by the original
study arm allocation. As before, children with temporary
conditions (e.g., cold sores, abrasions, or systemic ill-
nesses) will not have FV applied, but will remain in the
study. Children absent at this or subsequent visits will
also continue in the study unless actively withdrawn by a
parent or following assessment of any adverse reaction.
Visit 4: 12 Month (+/- 3 months) intervention visit to
nursery school
Procedures as for Visit 3 above.
Visit 5: 18 Month (+/- 3 months) intervention visit to
nursery school
Procedures as for Visit 3 above. If necessary, this visit
may take place in the first term of the child’s first year in
Primary school. Relevant school staff will be informed if
this required.Visit 6: 24 Month (+/- 3 months) end of study dental
examination visit to primary school
This visit will be conducted when participating children
are in Primary One, and 5 years old on average. The
final dental examination will be carried out, regardless of
whether or not the sequence of varnish applications or
TAU contacts had been interrupted or discontinued for
any reason.
Unexpected end of study visit
In the event of a child having to leave the study due to
withdrawn consent, or moving home and so on, the
head teacher of the school will inform the study team. If
the parent agrees, arrangements will be made to
complete the end-of-study dental inspection in order to
maintain that child in the study database.
Study outcome measures
Primary outcome measure
The primary outcome measure is d3mft at 2 years of fol-
low up compared to the d3mft at baseline (d3mft is den-
tal decay as measured by the number of: teeth affected
by decay into the dentine; missing teeth; and filled
teeth).
Secondary outcome measures
d3mfs The d3mfs scale is a count of affected surfaces ra-
ther than teeth. The d3mft and d3mfs measures will be
obtained through detailed dental examinations which
follow the protocol adopted for the NHS Scotland
National Dental Inspection Programme (NDIP), which
involve P1 and P7 children. The examinations will be
conducted by NDIP dentists following a training and
calibration exercise. In addition, dental decay outcomes
will be assessed by deprivation SIMD strata.
Child records of dental treatment and attendance
With parental informed consent, the children’s records
of dental treatment and attendance held by Information
and Statistics Division, NHS Scotland, will be examined
to establish a profile of contact with and treatment by
dental services in the two arms of the study.
Quality of life In addition to clinical data, the trial will
also collect data on children’s’ general and oral health
and quality of life using a battery of questionnaires, dis-
tributed at three points in the trial: at baseline,
12 months and 24 months. Parents/guardians of partici-
pants will be asked to complete:
– The Child Health Utility 9D for under 5-year-old
children (CHU9D) – parental proxy questionnaire
([23, 27], and Katherine Stevens, personal
communication, May-June 2014) (Additional file 2);
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the PedsQL 4.0 Generic Core Scale Parental Report
for Toddlers (ages 2–4 years) [29, 22, 30]
(Additional file 3);
– The Scale of Oral Health Outcomes for 5-year-old
children (SOHO-5), parental proxy questionnaire
([25, 26], and Georgios Tsakos personal communica-
tion, May 2014) (Additional file 4).
Health and dental care services resource use A ques-
tionnaire (Additional file 5) designed to elicit informa-
tion on uptake of health and dental care services and
medication use by the child within the past 12 months
will also be distributed in the quality of life question-
naire pack at each of the three rounds.
Subjective global transition judgement question
Parents/guardians will be asked to answer two subjective
global transition judgement questions in the question-
naire packs (Additional file 6) distributed at 12 and
24 months. This will be used as a method to assess the
QoL instruments’ responsiveness to change [1]. The
questionnaire packs will be distributed to the families
via the nurseries or posted to the family’s home address.
Follow-up procedures parental questionnaire survey
A number of well-established techniques to enhance re-
sponse rates will be used. These are:
– the cover page (Additional file 7) for the
questionnaire pack sent at baseline offer parents/
guardians the opportunity to enter a prize draw for
an iPad. This offer will be repeated for each of the
two subsequent rounds of the survey;
– there will be an unconditional incentive in the form
of a Childsmile branded pen and a page of
Childsmile stickers (for the child) contained within
the questionnaire pack;
– a sense of participation in the study will be
encouraged by the distribution of Christmas cards
and/or a study newsletter updating on the progress
of the study, and encouraging completion of the
parental questionnaires;
– parents who had previously provided a mobile
telephone number will receive a text reminder if
they have not returned the questionnaires within
1 week;
– at the end of the second week a second copy of the
questionnaire pack will be mailed to any
non-responders directly to their home address or
distributed via the child’s nursery;
– at the end of the third week the non-responder
parent will be contacted by telephone to remind
them to complete the questionnaires.The techniques described above have been adapted
from those used by the Seal or Varnish trial [5] run by
South East Wales Trials Unit/Cardiff University.
Data linkage
In order to be able to link the trial outcome measures by
child with the children’s records of dental treatment and
attendance held by Information and Statistics Division,
NHS Scotland, we will request, at the beginning of the
trial, a full home address from the parents/guardians of
trial participants.
Laboratory tests
None.
Assessment of safety
As part of the recruitment process, parents will be asked
about contraindications for fluoride varnish. The most
common of these are a history of hospitalisation for
bronchial asthma or allergic reactions. Other contraindi-
cations are: hypersensitivity to colophony and/or any
other fluoride varnish constituents.
Temporary conditions such as ulcerative gingivitis and
stomatitis will be checked on the day of the application,
following the normal Childsmile procedure detailed
below. This procedure is within the clinical remit of the
Extended Duty Dental Nurses employed to deliver the
Childsmile Fluoride Varnish programme, and includes
the following steps:
– check the skin of the face and around the mouth for
abnormalities (spots, inflammation, swelling etc.)
– check the lips for lesions/infections.
– check the inner cheeks and the insides of the lips
– check the upper and lower surfaces of the tongue.
– Children showing obvious signs of systemic illness
(e.g., colds, flu) or any abnormality of the face, lips
or soft tissues of the mouth should be excluded on
the day from Fluoride Varnish application.
– The teeth and gums should be checked for signs of
infection in a systematic order.
Adverse reaction reporting
If there are any immediate adverse reactions to the
Fluoride Varnish (e.g., mucositis, allergy etc.) the product
will be removed by toothbrushing and rinsing, following
the Childsmile local protocol. The possible adverse reac-
tion may be noticed immediately by the dental team or
later by the teachers or parents. Any such reports will be
transmitted by the Childsmile study team to the family
dentist, the Childsmile coordinator and the local Princi-
pal Investigator. This information will be updated on the
child’s notes accordingly.
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Children who are eligible for the study will be rando-
mised to receive fluoride varnish treatment as Duraphat®
Dental Suspension. Further details of treatment sched-
ules are given below.Treatment schedule
At each treatment, a total volume of 0.25 ml of Dura-
phat® Dental Suspension will be applied to the teeth in
children randomised to the intervention treatment. Each
1 ml of Duraphat® Dental Suspension contains 50 mg so-
dium fluoride which is equivalent to 22.6 mg of fluoride.
The protocol treatments will be applied at six monthly
intervals for 18 months i.e., baseline, and at 6 months,
12 months and finally 18 months post-baseline (all tim-
ings +/- 3 months).Rationale for chosen treatment schedule
The treatment schedule chosen is in line with current
practice guidelines (Guideline 83. [20]) and the approved
summary of product characteristics.
A 0.25 ml dose of Duraphat® dental suspension con-
tains 5.6 mg of fluoride. The toxic dose of fluoride inges-
tion is estimated at 75 mg for an average sized 3 year
old weighing 15 kg, so such a child would have to swal-
low 2 whole cartridges to ingest a toxic amount. Any
child suspected of swallowing excessive levels should be
given lots of milk to drink and transferred to the local
A&E Department for a gastric lavage [9].
A child in the study may receive fluoride varnish up to
a maximum of four times a year (twice in study applica-
tions and twice from their own dentist if their practice is
participating in their Childsmile Practice programme.)
This represents a total dose of 22.6 mg of fluoride
spread over four applications per year, and is well within
the Scottish Dental Clinical Effectiveness Programme’s
(SDCEP) clinical guidelines [15] and is within the safe
limits for both acute toxicity levels and chronic ingestion
resulting in fluorosis. Even if the child were to receive
two doses on the same day, there would be no risk of
toxicity as two doses would give the child 11.3 mg of
available fluoride, still well within the dose safety margin.
There would also be very little chance of fluorosis as,
after the age of 4 years, most of the adult teeth have
already calcified. A dose of 25 mg four times per year is
within the SDCEP’s clinical guidelines [15].Investigational product administration
The procedure will follow the standard practice of the
Childsmile Nursery programme [13] and will be detailed
in full in the study management procedures. An outline
of the procedure is given below.Safety assessment prior to treatment A safety assess-
ment procedure will be carried out by the team prior to
each treatment application. The safety assessment re-
duces the possibility of children with oral/facial infec-
tions being included. Any child with any abnormality of
the lips, face or soft tissues of the mouth will be ex-
cluded from fluoride varnish treatment scheduled for
that day. Children who are showing obvious signs of sys-
temic illness e.g., colds, 'flu, chicken pox etc. will also be
excluded on that day. An extra-oral and intra-oral as-
sessment will be conducted. Thereafter, the teeth and
gums will be checked for signs of infection starting with
the upper right and then moving to the upper left, lower
right and finally the lower left. If the risk assessment is
negative the fluoride varnish will be applied. Children
who have signs of decay will still have the fluoride var-
nish applied as it may help protect from further decay
and it will familiarise the child to dental treatment.
Treatment Starting with the upper right side, the cheek
will be retracted with a finger or mirror and the canine
and molars dried with a cotton roll. With the cotton roll
in place, a small amount of Fluoride Varnish will be ap-
plied to the contact points of the canine and molars and
to the occlusal surfaces of the molars. The same proced-
ure will be repeated for the upper left quadrant and
lower quadrants. The remaining varnish will be applied
to the labial surfaces of the canines and incisors. The
dental nurse will then complete a check to ensure that
all equipment is removed from the mouth and disposed
of in line with current procedures.
If the child becomes upset or protests during any part
of the procedure, then the procedure will be halted, and
only resumed if the child can be reassured and put at
ease. If any immediate adverse reaction is suspected, the
varnish can be easily removed by toothbrushing, rinsing
and spitting. Children who miss one or more of the
treatments are still eligible to receive any remaining
treatments. Children with an incomplete record of treat-
ments or contacts will be retained in the study, even if
all treatments and contacts are missed.
Study supplies
Supply of study treatment
Commercially available UK supplies of Duraphat® Dental
Suspension will be used in the study. All supplies for use
in the study will be sourced from via normal NHS supply
mechanisms. There will be no study specific supplies.
Duraphat® Dental Suspension is presented in 10 ml
aluminium tubes. As per current standard practice, each
tube will be used for multiple participants. In order to
prevent any potential cross-contamination, a single
0.25 ml dose will be measured out by the dental nurse
prior to the start of the procedure and the resealed tube
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box. Any Duraphat® Dental Suspension which remains at
the end of 7 days will not be used for study purposes.
Labelling of study treatment
There will be no study specific labelling. All supplies to
be used in the study will be UK licensed stock prescribed
by a dentist and labelled in accordance with current
regulatory requirements for Prescription Only Medicines
including instructions for use, expiry date and batch de-
tails. The investigational product will be used in accord-
ance with the Summary of Product Characteristics for
multiple study participants within a clinic type setting
under a dentist prescription and will not be dispensed
for use by an individual participant. To ensure traceabil-
ity, the batch number will be recorded at each partici-
pant treatment.
Storage of study treatments
As this is a phase IV study of an established treatment
intervention conducted as part of a national programme,
continuous temperature monitoring of the investiga-
tional medicinal product would be logistically difficult to
achieve and, from a risk perspective based on the clinical
use of the medicine, in excess of current practice stan-
dards. However in an effort to balance any potential
risks associated with limited exposure to temperatures
outwith the recommended storage temperature of 25oC,
opened tubes will be discarded after 7 days.
Drug accountability
In order to ensure full traceability, the batch number
used for each treatment of every individual participant
will be recorded on the Case Report Form. Details will
also be recorded on the CRF where there is only partial
application.
Pharmacovigilance
Definitions of adverse events
Adverse Event (AE) Any untoward medical occurrence
in a subject to whom a medicinal product has been ad-
ministered, including occurrences which are not neces-
sarily caused by or related to that product.
Adverse Reaction (AR) Any untoward and unintended
response in a subject to an investigational medicinal
product which is related to any dose administered to
that subject.
Serious Adverse Event (SAE) or Serious Adverse Reaction
(SAR)
Any adverse event or adverse reaction that:
– results in death,– is life threatening,
– requires hospitalisation or prolongation of existing
hospitalisation,
– results in persistent or significant disability or
incapacity,
– consists of a congenital anomaly or birth defect,
– is otherwise considered medically significant by the
investigator,
– Important adverse events/reactions that are not
immediately life-threatening or do not result in
death or hospitalisation but may jeopardise the
subject or may require intervention to prevent one
of the other outcomes listed in the definition above.
Suspected Serious Adverse Reaction (SSAR)
Any adverse reaction that is classed in nature as serious
and which is consistent with the information about the
medicinal product in question set out in the summary of
product characteristics (SmPC) or the Investigator’s Bro-
chure (IB).
Suspected Unexpected Serious Adverse Reaction (SUSAR)
Any adverse reaction that is classed in nature as serious
and which is not consistent with the information about
the medicinal product in question set out in the SmPC
or the Investigator’s Brochure (IB).
Detection, recording and reporting of Adverse Events
It is not proposed to collect details of all adverse events
occurring in this study. Only information on adverse re-
actions to the IMP will be collected. The applications
are spaced approximately 6 months apart, and it is in-
appropriate and unnecessary to attempt to collect infor-
mation throughout each 6 month period on events
unrelated to the varnish application, when it is known
what the very specific, immediate and limited range of
possible adverse reactions may be. Any adverse reaction
is extremely likely to be seen within a maximum of 24 h
post application. Any adverse events reported by parents
during that time will be recorded and evaluated by the
Childsmile coordinator and the local Principal Investiga-
tor irrespective of whether it constitutes a possible reac-
tion or an unconnected event.
All Adverse reactions must be recorded, notified,
assessed, reported, analysed and managed in accordance
with the Medicines for Human Use (Clinical Trials) Reg-
ulations 2004 (as amended) and this protocol. (See
Safety Flow chart- Additional file 8).
Any adverse reactions to the fluoride varnish (e.g., mu-
cositis, allergy etc.), whether noted by Childsmile staff or
reported to Childsmile staff by parents or the nursery
school, will cause either the study dental nurse or dental
health support worker to record details in the Case Re-
port Form and to inform the site Principal Investigator
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refer to the fluoride varnish aftercare leaflet for details of
the local Childsmile Coordinators acting as the contact
point regarding any possible adverse reaction.
The site Principal Investigator will assess the severity
and seriousness of such events, and re-assess their related-
ness to the administration of Duraphat varnish. Events
deemed to be serious and related to the administration of
the varnish will be classified as serious adverse reactions
(SARs). SARs are to be reported by the site to the Spon-
sor’s Pharmacovigilance Office within 24 h of awareness
of such event for assessment against the criteria of expect-
edness. The management of SARs is detailed below.
The expectedness of an adverse reaction is assessed
against the approved Reference Safety Information i.e.,
the list of expected reactions detailed in the SmPC.
The following is noted in the SmPC:
“In subjects with a tendency to allergic reactions,
oedematous swelling of the oral mucosa has been
observed in exceptional cases, especially after extensive
application. If necessary, the dental suspension layer
can easily be removed from the mouth by brushing and
rinsing. Ulcerative gingivitis and stomatitis have been
reported by sensitive individuals.
In rare cases, asthma attacks may occur in participants
who have bronchial asthma.
In participants with gastric sensitivity, retching may
exceptionally occur after a high dosage and extensive
application.”
The expectedness of a SAR will be determined by the
Chief Investigator following discussion with the site
Principal Investigator.
Severity
This should be assessed and described using the follow-
ing categories:
– mild-awareness of event but easily tolerated,
– moderate-discomfort enough to cause some
interference with usual activity,
– severe-inability to carry out usual activity.
Any AE that is assessed as serious, is suspected of hav-
ing a causal relationship to the trial medication and is
unexpected is a SUSAR and will require expedited
reporting to the MHRA/Ethics Committee as detailed
below. Should an SAR be deemed to be unexpected, the
Pharmacovigilance Office will liaise with the Chief Inves-
tigator to complete the expedited safety report.
Adverse reactions and Serious Adverse Reactions that
occur up to 24 h after Fluoride varnish application will
be reported.Any adverse reactions present at the last application
must be followed up until the event is resolved. The par-
ticipant is considered to have completed the study
EITHER after the completion of the last visit or contact
(e.g., phone contact with the site Principal Investigator),
OR after the last application of fluoride varnish, which-
ever is later; OR the participant can no longer comply
with the requirements for any further study visits or
evaluations.
Reporting of serious adverse reactions
All SARs (as detailed above) arising during the study will
be reported by the site Principal Investigator or site
Childsmile study team following review by the Principal
Investigator to the sponsor (Glasgow Clinical Trials Unit
(GCTU) Pharmacovigilance (PV) Office) as soon as rea-
sonably practicable and in any event within 24 h of first
becoming aware of the event. Any follow up information
should also be reported.
A Serious Adverse Event form is completed and for-
warded to the Pharmacovigilance Office.
– The GCTU Generic CTIMP SAE form is
downloaded from www.glasgowctu.org, printed off,
completed and signed. The form is then faxed to the
Pharmacovigilance Office on 0141 357 5588. A copy
is placed in the Study Site File.
– If necessary a verbal report can be given by
contacting the Pharmacovigilance Office on 0141
330 4744. This must be followed up as soon as
possible with a signed written report.
Serious adverse reaction details will be transferred to
the Glasgow Pharmacovigilance database.
All SUSARS must be reported in an expedited fashion
to the MHRA and Ethics Committee
– Fatal or life threatening SUSARs: not later than
7 days after the sponsor had information that the
case fulfilled the criteria for a fatal or life threatening
SUSAR, and any follow up information within a
further 8 days.
– All other SUSARs: not later than 15 days after the
sponsor had information that the case fulfilled the
criteria for a SUSAR
The Pharmacovigilance office will report SUSARs to
the MHRA on behalf of the Chief Investigator via the
MHRA eSUSAR reporting system and to Ethics commit-
tee by email.
Annual safety reporting
An annual safety report is required to be submitted to
MHRA and REC within 60 days of the anniversary of
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Investigator will submit this report in liaison with the
Pharmacovigilance Office.
Statistics and data analysis
Statistical analysis plan
The study will have a comprehensive Statistical Analysis
Plan, which will govern all statistical aspects of the
study, and will be authored by the trial statistician and
agreed by the Trial Management Group (TMG) before
any unblinded data is seen.
Binary endpoints such as evidence of any new decay
will be analysed by Mantel-Haenszel Chi-squared tests
and odds-ratios, with the attendant 95 % confidence in-
tervals. This type of analysis will also be carried out on
safety event data. Changes in d3mft will be analysed by
Wilcoxon tests, unless these changes are normally dis-
tributed and therefore suitable for analysis by Analysis of
Covariance. Compliance will be compared with a chi-
squared test. The subgroup analyses will be carried out
for the primary endpoint using logistic regression with
interaction terms between treatment and subgroup. All
statistical tests will be two-tailed tests at the 5 % signifi-
cance level. There should be no concerns regarding mul-
tiple testing. All randomised controlled trials examine
secondary endpoints to examine consistency of results
and to generate hypotheses for further research.
All analyses will follow the intention to treat principle
[8, 11]. Study subjects will be analysed in their rando-
mised groups regardless of the treatment actually re-
ceived. Also, subjects who violate the rules of the study
(‘protocol violators’) will be included in all of the ana-
lyses, provided that the 2 year endpoint data has been
recorded. Ideally an intention to treat analysis would be
carried out on all of the randomised subjects, but there
is usually some missing primary endpoint data that pre-
vents this. We will also carry out a ‘Worst Case Analysis’
of the Primary Endpoint. In this analysis the missing
endpoints will be assumed to be treatment failures, e.g.,
‘new decay’.
Primary efficacy analysis
The primary outcome measure is d3mft at two years of
follow up compared to the d3mft at baseline (d3mft is
dental decay as measured by the number of: teeth af-
fected by decay into the dentine; missing teeth; and filled
teeth). The primary analysis is the comparison between
the treatment groups in percentages of children experi-
encing new decay as defined by the primary endpoint,
namely an increase in d3mft.
Secondary efficacy analysis
Secondary analyses will be of:– absolute change in d3mft at 2 years of follow up
minus the d3mft at baseline,
– absolute change in d3mfs at 2 years of follow up
minus the d3mfs at baseline.
We will do pre-defined subgroup analyses on the fol-
lowing types of subgroup:
– children with pre-existing disease, children without
pre-existing disease,
– we will attempt to split the children into areas that
are ‘extremely’ deprived and only ‘very deprived’
based on the SIMD of the child’s postcode.
Safety analysis
The safety data (adverse reactions) – both numbers of
subjects and reactions – will be summarised by rando-
mised group and overall using descriptive statistics. No
formal statistical tests comparing the randomised groups
will be pre-specified.
Software for statistical analysis
SAS 9.4 software for Windows, Cary, NC, USA.
Sample size
Assuming that prevalence data on childhood caries de-
velopment in the recent literature are roughly applicable,
if none of the 3 year olds with existing disease had
‘worsened’, then 24.65 % (57.63–32.98 %) would have ex-
perienced new decay. If all of the 5 year olds with decay
had worsened then 57.63 % could have experienced new
decay. The half-way point between these minimum and
maximum percentages is therefore 41.14 %. We therefore
roughly estimate that 41 % of 3 year olds will experience
new decay over the course of 2 years of follow-up.
In the study of older children by Skold et al. [21] it
was found that 6 month treatment by fluoride varnish
for 3 years reduced the development of new caries or le-
sions by 54.7 % in the high risk group (75 % new decay
for controls versus 34 % in the varnish group). If we
multiply 54.7 % by two thirds to roughly approximate
the effect of following up for 2 years rather than 3 years
we would get a reduction of around 36.5 % in the devel-
opment of new lesions or caries.
A 36.5 % reduction from 41 % would equal 41–
41%x0.365 = 26.035 %. However, the Skold study was
carried out in much older children with greater levels of
decay, and our treatment will be nested within a public
health intervention that includes provision of fluoride
toothpaste. If we took a more cautious approach to the
effect size of the treatment we could compare a 41 %
worsening in the control group to a 31 % worsening in
the treatment group (a 24 % reduction).
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cance level of 0.05 will have 90 % power to detect the
difference between a Group 1 proportion of 0.41 and a
Group 2 proportion of 0.31 (an odds ratio of 1.55) when
the sample size in each group is 483. We therefore need
a total of 966 evaluable subjects. Allowing for a pessim-
istic dropout rate of 40 %, we would need to randomise
805 subjects in each of the two groups, giving a total
number of 1610 subjects to be randomised.
Economic evaluation
The economic evaluation of the Protecting Teeth at 3
Study will commence in August 2014 and will initially
include the three NHS Boards that will have a new in-
take of participants into the trial in the autumn-winter
2014/15: NHS Fife, NHS Lothian and NHS Tayside.
Economic evaluation perspective This economic evalu-
ation will be conducted from the UK NHS perspective.
The incremental costs and benefits of the fluoride var-
nish intervention over and above TAU only will be
reported.
Economic evaluation data sources Trial-related NHS
resource use will be estimated using the information
from direct enquiries to the trial coordinators, and from
a staff costs questionnaire (Additional file 9). The trial
coordinators in each participating health board will be
asked to provide a list of consumables, reusable and dis-
posable items costs (which are identical per individual
child in the intervention/control group). The coordina-
tors will also be asked to provide information on the job
band of each of their PTat3 Study NHS staff. For each
trial-related visit to a participating nursery the trial staff
will fill in a staff costs questionnaire, which contains
questions on the time spent in a nursery delivering inter-
ventions, distance travelled (calculated from postcodes of
the origin and destination of journeys) and the number
and type of vehicles involved in a visit to the nursery.
The previously described combined outcome/QoL
questionnaire tool (see Chapter 4.2.2) will be used in
order to assess the oral/general health related quality of
life of the child-participants. The CHU9D will allow the
calculation of QALYs, while the other outcome question-
naires will provide data on oral/general health related
quality of life scores only.
Economic evaluation methods The incremental costs
and benefits of the fluoride varnish intervention over
and above TAU only will be explored. The relationship
between the general health and oral health related qual-
ity of life measures and the d3mft/d3mfs outcomes will
be assessed using linear regression methods. A CAU will
be also performed: with the outcome measure beingQALYs, calculated using responses to the CHU9D
questionnaires.
Both costs and health outcomes will be discounted at
the same annual rate of 1.5 % as per the public health
reference case [14].
Sensitivity analysis will be performed by varying such
parameters as the costs of labour (via changing the skill
mix of the intervention team by combining staff mem-
bers of various job bands) and the time the trial staff
spent to deliver the interventions to each child. The re-
sults of the economic evaluation will be reported via a
cost-effectiveness plane and cost-effectiveness accept-
ability curve (CEAC) using currently accepted values of
willingness to pay thresholds for a QALY (according to
the National Institute for Health and Care Excellence
(NICE) guidelines, [14, 28]).
Management and delivery
The RCB, part of the Glasgow Clinical Trials Unit, a
fully registered UK CRN Clinical Trials Unit, will man-
age the trial data. All statistical analyses will be con-
ducted according to the SAP specified above.
Trial closure/Definition of end of trial
The trial will end when the TMG agrees that one or
more of the following situations applies;
– last participant last study visit,
– there is insufficient funding to support further
recruitment, and no reasonable prospect of
additional support being obtained,
– new information makes it inappropriate to continue
to randomise participants to one or other arm of the
trial,
– recruitment is so poor that completion of the trial
cannot reasonably be anticipated.
Within 90 days of end of trial, the Chief Investigator
will submit the Declaration of End of a Clinical Trial
documentation to the MHRA and Ethics Committee.
The declaration of the end of a clinical trial form is
available from EudraCT: European Clinical Trials web-
site (https://eudract.ema.europa.eu/docs/forms/Declara-
tion_Of_The_End_Of_Trial.doc). The submission of the
end of trial study final report to the MHRA and Ethics
Committee should be made by the Chief Investigator
within 12 months of trial closure. The Sponsor should
be notified that the Declaration of End of a Clinical Trial
and End of Study final report has been made to the rele-
vant bodies.
Data handling
There are three distinct phases to study data management.
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participants.
Phase 2. Dental examinations and randomisation
Phase 3. Intervention (varnish/control) activity
recording.
Randomisation
The central randomisation facility at the Robertson
Centre for Biostatistics, University of Glasgow (inter-
active voice response system, IVRS) will allocate children
to each study arm. A central unblinding facility at the
Robertson Centre will also be available by telephone.
Notification of any unblinding will be sent to the Chief
Investigator.
Case report forms/Electronic data record
Paper case report forms (CRFs) will be used to collect
study data. Access to CRFs will be restricted, and they
will be delivered by hand to the Robertson Centre by
study personnel, with only authorised site-specific
personnel able to make entries or amendments to their
participants’ data. It is the investigator's responsibility to
ensure completion and to review and approve all data
captured in the CRFs.
All data handling procedures will be detailed in a
Study Specific Data Management Plan. Data will be vali-
dated at the point of entry into the CRF and at regular
intervals during the study. Data discrepancies will be
flagged to the study site and any data changes will be re-
corded in order to maintain a complete audit trail (rea-
son for change, date change made, who made change).
Record retention
To enable evaluations and/or audits from regulatory au-
thorities, the investigator agrees to keep records, includ-
ing the identity of all participating subjects (sufficient
information to link records), all original signed informed
consent forms, serious adverse event forms, source doc-
uments, and detailed records of treatment disposition in
accordance with ICH GCP, local regulations, or as speci-
fied in the Clinical Study Agreement, whichever is lon-
ger. Data will be retained at the Data Centre for a
minimum of 5 years.
Trial management
Routine management of trial: Trial Management Group
The trial will be coordinated from Community Oral
Health, Glasgow Dental School by the TMG. The TMG
will include those individuals responsible for the day-to-
day management of the trial, such as the Chief Investiga-
tor, statistician, trial manager, research nurse, data
manager. The role of the group is to monitor all aspects
of the conduct and progress of the trial, ensure that theprotocol is adhered to and take appropriate action to
safeguard participants and the quality of the trial itself.
Invitations have been made to a number of individuals
to sit on the Study Steering Committee, to meet twice a
year. Working groups within each participating Health
Boards have been set up, consisting of NHS and Univer-
sity representatives.
Study monitoring
Study Monitoring Visits will be conducted by NHS
Greater Glasgow and Clyde Monitor(s). The level of
monitoring will be based on the outcome of the com-
pleted monitoring risk assessment; however, the mini-
mum requirement per site will be an initiation visit
following the issue of all approvals, and prior to the start
of recruitment; a full monitoring visit when participants
have been randomised; and a close out visit at each site
after the last participant has completed the last visit. All
Informed Consent Forms will be reviewed; a minimum
of 10 % of subjects will be reviewed for Source Data
Verification; these will be chosen at random and will
consist of both subjects with reported SARs and those
without any reported SARs. Additionally, the monitors
will aim to review all SARs reported throughout the
study.
Prior to commencement of the trial a Monitoring Plan
will be written by the monitors and approved by the
Sponsor’s Governance Manager.
Protocol amendments
Any change in the study protocol will require an amend-
ment. Any proposed protocol amendments will be initi-
ated by the Chief Investigator and any required
amendment forms will be submitted to the regulatory
authority, ethics committee and sponsor. The Chief In-
vestigator will liaise with study sponsor to determine
whether an amendment is non-substantial or substantial.
All amended versions of the protocol will be signed by
the Chief Investigator and Sponsor representative. Before
the amended protocol can be implemented favourable
opinion/approval must be sought from the original
reviewing REC, MHRA and Research and Development
(R&D) office(s).
Ethical considerations
Ethical conduct of the study
The study will be carried out in accordance with the
World Medical Association Declaration of Helsinki
(1964) and its revisions (Tokyo 1975, Venice 1983, Hong
Kong 1989, South Africa 1996, Edinburgh 2000, and
Seoul 2008). Favourable ethical opinion will be sought
from The West of Scotland Research Ethics Committee
1 before participants are entered into this clinical trial.
Study participants will only be allowed to enter the study
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ten informed consent. The Chief Investigator will be re-
sponsible for updating the Ethics committee of any new
information related to the study.Informed consent
Written informed consent will be obtained from a par-
ent or legal guardian, as applicable, of each trial partici-
pant. A participant information sheet and consent form/
contraindications check will be distributed via the nur-
sery school 2–3 weeks in advance of the consent visit
and/or at least 24 h prior to consent being sought on a
face-to-face basis, when a study team member present at
the nursery school will explain the exact nature of the
study, answer any questions and address any concerns.
This explanation will include the known side-effects that
may be experienced, and the risks of participating in this
clinical trial. Trial participants will be informed that they
are free to withdraw their consent from the study or
study treatment at any time. Parents can return consent/
contraindications check information to the nursery
schools or at the face-to-face consent visit.Insurance and indemnity
The Protecting Teeth At 3 Study is co-sponsored by
NHS Greater Glasgow & Clyde and The University of
Glasgow. The Co-sponsors will be liable for negligent
harm caused by the design of the trial. NHS indemnity
is provided under the Clinical Negligence and Other
Risks Indemnity Scheme (CNORIS). As the substantive
employer of the Chief Investigator and as co-sponsor of
the The Protecting Teeth At 3 Study, The University of
Glasgow also has insurance with Royal and Sun Alliance.
It will be confirmed prior to the trial starting that insur-
ance cover will be provided automatically under the
current policy. The insurance cover will be subject to
NHS indemnity being in place and Ethics Committee
approval being obtained.
The NHS has a duty of care to participants treated,
whether or not the participant is taking part in a clinical
trial, and the NHS remains liable for clinical negligence
and other negligent harm to participants under its duty
of care.
As this is a clinician-led study there are no arrange-
ments for no-fault compensation.Funding
This study is being funded as part of the evaluation
programme built in to the Childsmile programme, and is
therefore funded by the Scottish Government independ-
ently of any grant awarding process.Co-sponsor responsibilities
Prior to study initiation, a non-commercially funded
clinical trial co-sponsorship agreement will be put in
place between NHS Greater Glasgow & Clyde and The
University of Glasgow. The roles and liabilities each or-
ganisation will take under The Medicines for Human
Use (Clinical Trials) Regulations, 2004 SI 2001:1031 are
laid out in this agreement signed by both organisations.
The University of Glasgow shall be responsible for carry-
ing out the obligations and responsibilities set out in the
aforementioned agreement, and shall be deemed “spon-
sor” for the purposes of Part 3 of the regulations in rela-
tion to the study. NHS Greater Glasgow & Clyde shall
be responsible for carrying out the responsibilities set
out in the agreement, and shall be deemed “sponsor” for
the purposes of Parts 4, 5, 6 and 7 of the Regulations in
relation to the study.
Annual reports
Annual reports will be submitted to the ethics committee,
regulatory authority and sponsor with the first submitted
1 year after the date that all trial related approvals are in
place.
Dissemination of findings
Study findings for the study will be reported through the
six-monthly internal reports generated by the Childsmile
Central Evaluation and Research Team. Study team
members will collaborate on the production of papers to
be submitted to peer-reviewed journals and abstracts of
proposed presentations at national and international
conferences and symposia.
Additional files
Additional file 1: MHRA Notification of trial. (PDF 53 kb)
Additional file 2: CHU9D questionnaire – Nursery version.
(DOCX 79 kb)
Additional file 3: PedsQL questionnaire – Nursery version.
(DOCX 129 kb)
Additional file 4: SOHO-5 questionnaire. (DOCX 48 kb)
Additional file 5: Child’s use of health and dental care services
questionnaire. (DOCX 20 kb)
Additional file 6: Subjective global transition judgement questions.
(DOCX 24 kb)
Additional file 7: Questionnaire Cover Sheet – Round 1.
(DOCX 27 kb)
Additional file 8: Flowchart for Assessing and Reporting Adverse
Reactions. (DOCX 38 kb)
Additional file 9: Trial staff costs questionnaire. (DOCX 445 kb)
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